NCT05429632

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 366 (estimated)
• Sponsor: Priothera SAS · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, double-blinded, placebo controlled trial.

Detailed description

The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT).

Conditions

• Adult Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	mocravimod	S1PR modulator

Timeline

• Start date: 2022-06-16
• Primary completion: 2027-05-01
• Completion: 2029-11-01
• First posted: 2022-06-23
• Last updated: 2026-04-17

Locations

108 sites across 14 countries: United States, Argentina, Brazil, France, Germany, Israel, Italy, Japan, Poland, Romania, Spain, Switzerland, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study